Xenetic Biosciences (XBIO)
(Real Time Quote from BATS)
$2.99 USD
-0.18 (-5.53%)
Updated Aug 6, 2025 01:30 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XBIO 2.99 -0.18(-5.53%)
Will XBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XBIO
USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates
Progyny (PGNY) Tops Q3 Earnings Estimates
XBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Other News for XBIO
XBIO Partners with PeriNess for Innovative Lymphoma Study
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study ...
Xenetic says PeriNess enters clinical study agreement for DNase Platform
Xenetic (XBIO) Advances Collaboration with The Scripps Research Institute | XBIO Stock News
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps ...